CompanyGraph
What stands out
- Most companies in its industry are risk businesses; this one is a production business
At a glance
- Depends onUpstream position: supplies 3 industries, depends on 0
- ScaleMarket cap is $16.81M, lower than 95% of all stocks globally
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are risk businesses; this one is a production business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
As of FY2024 (year ended December 31, 2024). Newer annual figures aren't yet on file.
Financials view
Market Capitalization
12.45MGBP16.81M · vs all stocks (USD)
Revenue (TTM)
263.00KGBP355.19K · vs all stocks (USD)
52-Week Change
2784.34%vs all stocks
Market Capitalization
12.45MGBP16.81M · vs all stocks (USD)
Enterprise Value
27.33MGBP36.91M · vs all stocks (USD)
Price to Sales (TTM)
47.33xPrice to Book (MRQ)
2.68xvs Shell Companies peers
Enterprise to Revenue
103.91xEnterprise to EBITDA
-13.93xvs Shell Companies peers
Operating Margin
-42.97%Return on Assets (TTM)
-5.74%vs Shell Companies peers
Return on Equity (TTM)
-129.17%Revenue (TTM)
263.00KGBP355.19K · vs all stocks (USD)
Revenue per Share (TTM)
0.0010GBPUpdated Jul 28, 2026Quarterly Revenue Growth
209.40%Gross Profit (TTM)
255.00KGBP344.39K · vs all stocks (USD)
EBITDA (TTM)
-1.96MGBP-2.65M · vs all stocks (USD)
Net Income (TTM)
-6.79MGBP-9.17M · vs all stocks (USD)
Operating Cash Flow (TTM)
-2.53MGBP-3.42M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-4.05MGBP-5.47M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00GBPUpdated Jul 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
1.53MGBPFY2024 · Dec 31, 2024Revenue
85.00KGBPFY2024 · Dec 31, 2024Cost of Goods Sold
34.00KGBPFY2024 · Dec 31, 2024Gross Profit
51.00KGBPFY2024 · Dec 31, 2024Operating Income
-3.25MGBP-4.39M · vs all stocks (USD)
Pre-tax Income
-11.46MGBPFY2024 · Dec 31, 2024Income Tax Expense
3.00KGBPFY2024 · Dec 31, 2024Net Income
-11.46MGBPFY2024 · Dec 31, 2024EBIT
-10.62MGBPFY2024 · Dec 31, 2024EBITDA (Income Statement)
-4.98MGBPFY2024 · Dec 31, 2024Selling, General & Administrative
2.47MGBPFY2024 · Dec 31, 2024Non-operating Interest Expense
835.00KGBPFY2024 · Dec 31, 2024EPS (Basic)
-0.0510GBPFY2024 · Dec 31, 2024EPS (Diluted)
-0.0510GBPFY2024 · Dec 31, 2024Basic Shares Outstanding
152.10MSharesFY2024 · Dec 31, 2024Diluted Shares Outstanding
152.10MSharesFY2024 · Dec 31, 2024Minority Interests (P&L)
473.00KGBPFY2024 · Dec 31, 2024Preferred Stock Dividends
0.00GBPFY2024 · Dec 31, 2024Operating Cash Flow
-7.15MGBPFY2024 · Dec 31, 2024Free Cash Flow
-10.78MGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents (End of Period)
375.00KGBPFY2024 · Dec 31, 2024Starting Profit (CF Statement)
-11.46MGBPFY2024 · Dec 31, 2024Stock-based Compensation
1.45MGBPFY2024 · Dec 31, 2024Other Non-cash Items
2.39MGBPFY2024 · Dec 31, 2024Change in Accounts Receivable (CF)
630.00KGBPFY2024 · Dec 31, 2024Change in Other Assets/Liabilities
-163.00KGBPFY2024 · Dec 31, 2024Capital Expenditures
-3.62MGBPFY2024 · Dec 31, 2024Net Acquisitions
-1.12MGBPFY2024 · Dec 31, 2024Net Investing Cash Flow
-4.74MGBPFY2024 · Dec 31, 2024Long-term Debt Issuance
4.01MGBPFY2024 · Dec 31, 2024Long-term Debt Payments
-65.00KGBPFY2024 · Dec 31, 2024Net Financing Cash Flow
6.32MGBPFY2024 · Dec 31, 2024Shares Outstanding
331.91MSharesUpdated Jul 28, 2026Float Shares
213.21MSharesUpdated Jul 28, 2026% Held by Insiders
39.28%vs all stocks
% Held by Institutions
0.00%vs all stocks
Total Cash (MRQ)
706.00KGBP953.47K · vs all stocks (USD)
Total Cash per Share (MRQ)
0.0020GBPUpdated Jul 28, 2026Total Debt (MRQ)
14.12MGBP19.07M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.30xvs Shell Companies peers
Current Ratio (MRQ)
1.34xvs Shell Companies peers
Book Value per Share (MRQ)
0.0140GBPUpdated Jul 28, 2026Total Assets
21.55MGBP29.10M · vs all stocks (USD)
Total Current Assets
951.00KGBPFY2024 · Dec 31, 2024Total Liabilities
17.07MGBPFY2024 · Dec 31, 2024Total Non-current Assets
20.60MGBPFY2024 · Dec 31, 2024Total Non-current Liabilities
15.14MGBPFY2024 · Dec 31, 2024Total Current Liabilities
1.93MGBPFY2024 · Dec 31, 2024Cash
375.00KGBPFY2024 · Dec 31, 2024Cash & Cash Equivalents
375.00KGBPFY2024 · Dec 31, 2024Accounts Receivable
105.00KGBPFY2024 · Dec 31, 2024Inventory
163.00KGBPFY2024 · Dec 31, 2024Accounts Payable
395.00KGBPFY2024 · Dec 31, 2024Short-term Debt
404.00KGBPFY2024 · Dec 31, 2024Long-term Debt
15.14MGBPFY2024 · Dec 31, 2024Common Stock (Book)
38.36MGBPFY2024 · Dec 31, 2024Retained Earnings
-41.14MGBPFY2024 · Dec 31, 2024Total Shareholders' Equity
4.48MGBP6.05M · vs all stocks (USD)
52-Week High
16.50GBXUpdated Jul 28, 202652-Week Change
2784.34%vs all stocks
50-Day MA
5.08GBXUpdated Jul 28, 2026200-Day MA
7.06GBXUpdated Jul 28, 2026Avg 10-Day Volume
111.51KSharesUpdated Jul 28, 2026Avg 30-Day Volume
202.61KSharesUpdated Jul 28, 2026Diluted EPS (TTM)
-0.0300GBPUpdated Jul 28, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Most companies in its industry are risk businesses; this one is a production businessSignificant
Industry peers: 62.00Share on the common pattern %: 76.00
Supply Chain
Upstream position: supplies 3 industries, depends on 0Notable
Outgoing: 3.00Incoming: 0.00
Scale
Market cap is $16.81M, lower than 95% of all stocks globallySignificant
Market cap (USD): 16,809,679.93Global P5: 269,387,740.27
Revenue is $355,189, lower than 95% of all stocks globallySignificant
Revenue (USD): 355,189.39Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
BioLineRx Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Genflow Biosciences Plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Crism Therapeutics Corporation
Tier 1ProductionApproval-Gated PipelineRuleRisk
ImmuPharma PLC
Tier 1ProductionApproval-Gated PipelineRuleRisk
Sulzer Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Purple Biotech Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Poolbeg Pharma plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Faron Pharmaceuticals Oy
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pyridam Farma Tbk.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Roquefort Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRuleRisk